Marcus Boehm - 18 Apr 2022 Form 4 Insider Report for Vyant Bio, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 18 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Apr 2022, 19:35:12 UTC
Prior SEC filing: 01 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrew LaFrence, attorney-in-fact

Key filing fact

Marcus Boehm filed Form 4 for Vyant Bio, Inc. on 19 Apr 2022.

Key facts

This page summarizes Marcus Boehm's Form 4 filing for Vyant Bio, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Apr 2022, 19:35.

Change

Previous filing in this sequence was filed on 01 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYNT transaction

Common Stock, $0.0001 par value

Award

Transaction value
Shares: +7,281
Change %: +15%
Price
Shares after: 56,484
Date: 18 Apr 2022
Ownership: Direct
Footnotes: F1

VYNT holding

Common Stock, $0.0001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 128,786
Date: 18 Apr 2022
Ownership: By Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On April 18, 2022, the Reporting Person was granted 7,281 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on April 18, 2023, so long as Reporting Person remains a director though that date.